Hello, my name is Liz Dixon. I'm Tristel's Chief Financial Officer, today I'm going to give you a short presentation that will accompany the trading update that we released this morning, following our year ending 30th of June, 2023. This is the same presentation that we will be giving to our shareholders who attend our open day today. We'll be welcoming any of you who are able to make it, and I hope you all can, and meet the team and see the products in action. If you've been unable to attend today, hopefully this will give you a little bit of a sense of what we'll be talking about, and to give you an update on where we are. Our business is a global infection prevention company, and we focus upon the hospital. Our unique proposition is chlorine dioxide, our proprietary formulation, and we have two revenue segments. The first seeks to achieve decontamination of medical instruments by hand using foams and wipes and liquids, and the second seeks to eliminate the use of plastic wipes within hospitals by separating the disinfectant from the wipe. We have two ranges, two brand names: Tristel for medical devices and Cache for our surface disinfectant range. With our Tristel medical device decontamination range, we can address diagnostic services in every hospital in every country around the world. The departments that we focus upon are generally found within the outpatients area of the hospital, and they include ear, nose, and throat; obstetrics and gynecology, so women's health; cardiology, urology, ophthalmology, and emergency medicine. We estimate that there are 17 million procedures carried out using a Tristel decontamination product every year. We estimate that there are globally more than 1 billion procedures that our products would be appropriate for. We have a long way to go before we meet saturation point. In the last 10 years, we can calculate that a Tristel product has been used on more than 110 million medical devices to decontaminate them between patients. With our Cache surface sporicidal surface disinfection range, we can disinfect every surface in every hospital in every country around the world. To the year to 30th of June, we attained revenue of GBP 3.4 million with our Cache range. The total addressable market for these products is more than GBP 4 billion. Again, a long, long way to go. We've developed the business over the past 18 years internationally, and now that we have an FDA approval, we can truly say that we have a global footprint. Our HQ in the U.K is shown in purple on the map, and you can also see our 14 subsidiaries shown in green, and the 33 distributors that we partner with sell through an additional 33 countries. 65% of our revenues are derived from markets outside of the U.K. To help our shareholders, we like to share our goals and our ambitions for the future. The financial goals that we have set. that we've made visible to you over the course of the last six- years now, are to target annual revenue growth of 15% per annum, that will be between the years of 2022 and 2025, to achieve an EBITDA margin of 25% as a minimum. We will review both of these targets at the point of interims in February 2024, with a view to hopefully upgrading them. Looking back, we achieved compound annual growth of 13% per annum over the last 10 years. In 2017, our sales were 17 million GBP, it's taken us seven- years to double revenue. Two of the past three years were affected by Brexit and COVID, we saw flat growth. In the last year ending 30 June 2023, we reported growth of 16%. Now looking forward, our ambition is to double revenue. How will we do that? First of all, we will seek to sell more product to existing customers. In the list of departments within hospitals that we currently address, we not every hospital uses our products in every department, and not every department uses the products as widely as they might. We will seek to broaden the use of products in hospitals where we already have a relationship and are already selling. The second driver will be to create and sell new products, and here we have a list of what those are. First of all, the Cache product range that some of you will be familiar with, which is to achieve sustainable surface disinfection within a hospital. The second is digital traceability via our 3T app, and also two compliance and assurance products, Bisy-Blue, and also incorporating AI into our 3T app, which will enable our products to not just be the equal of our competitors, but actually to be far superior to them. The third driver, now that we have an FDA approval, is through to enter new countries. That includes a multi-product strategy within the United States, expanding that over to Canada. In India, we will take a new approach. We achieved our approval in India some years ago, but we've been unsuccessful in finding a partner who works for us. We are now seeking an alternative route to market in India. We're addressing the Philippines and Indonesia. The FDA approval most certainly opens doors for us within Central and South America. When will the doubling of revenue be achieved? If we hit our 15% growth target, it will be in 2028, with the impact of the Americas enhancing our growth rate, it can happen much earlier. All the interventions that will enable us to grow at this pace are made possible because we are a very profitable company. We achieve a gross profit margin of 80%, an EBITDA margin of 25%, and a return on capital employed of 21%. We are also very cash generative. This allows us to consistently increase our dividend, as you can see by the chart. What has all this meant for our shareholders? Well, for long-term shareholders, the returns have been very good. Our float price in 2005 was GBP 0.37, and our current share price is GBP 3.55. I think this is what could be referred to by some shareholders as a ten-bagger. The cumulative dividends paid over that period have been 62 pence per share, per 1 penny share, which means we have distributed cash of GBP 26.5 million. To summarize, ours is a simple, focused, global opportunity, and we believe that over the past 18 years, we've delivered good value to our shareholders. Much more importantly, we're very confident that we can continue to do so as we look into the future. Thank you.